Mirati Therapeutics, Inc. Contracts & Agreements

Position and Compensation Adjustment Letter, dated August 23, 2023, by and between (Filed With SEC on November 6, 2023)

Severance Policy for Senior Vice Presidents and Vice Presidents, dated October 11, 2022, by and between Mirati Therapeutics, Inc. and Aaron A. Ondrey (Filed With SEC on November 6, 2023)

Employment Agreement, dated June 29, 2022, by and between (Filed With SEC on November 6, 2023)

Consulting Agreement Amendment No 2., dated September 22, 2023, by and between (Filed With SEC on November 6, 2023)

Consulting Agreement Amendment No 1., dated September 12, 2023, by and between (Filed With SEC on November 6, 2023)

Consulting Agreement, dated September 9, 2023, by and between (Filed With SEC on November 6, 2023)

Separation Agreement and Release, dated August 7, 2023, by and between (Filed With SEC on November 6, 2023)

Agreement and Plan of Merger, dated as of October 8, 2023, by and among Bristol-Myers Squibb Company, Vineyard Merger Sub Inc., and Mirati Therapeutics, Inc (Filed With SEC on October 10, 2023)

Form of Pre-Funded Warrant (Filed With SEC on August 9, 2023)

Underwriting Agreement, dated August 8, 2023 (Filed With SEC on August 9, 2023)

Employment Agreement, dated April 12, 2023, by and between the Registrant and John B. Moriarty, Jr (Filed With SEC on August 8, 2023)

Non-Employee Director Compensation Policy, Amended and Restated June 22, 2023 (Filed With SEC on August 8, 2023)

2013 Employee Stock Purchase Plan, as amended (Filed With SEC on May 12, 2023)

Employment Agreement, dated August 17, 2022, by and between the Registrant and Alan Sandler, M.D (Filed With SEC on February 28, 2023)

Letter Agreement, dated December 16, 2022, by and between the Registrant and James Christensen (Filed With SEC on February 28, 2023)

Non-Employee Director Compensation Policy (Filed With SEC on February 28, 2023)

Mirati Therapeutics, Inc. Executive (Filed With SEC on November 8, 2022)

Employment Agreement, dated April 7, 2022, by and between the Registrant and Laurie D. Stelzer (Filed With SEC on August 3, 2022)

Separation Agreement and Release, dated December 15, 2021, by and between the Registrant and Dan Faga (Filed With SEC on February 28, 2022)

Amended and Restated Second Amendment to Letter Agreement, effective September 20, 2021, by and between the Registrant and Dr. James Christensen (Filed With SEC on February 28, 2022)

Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on February 28, 2022)

Underwriting Agreement, dated November 10, 2021 (Filed With SEC on November 12, 2021)

Employment Agreement, dated September 17, 2021, by and between the Registrant and David (Filed With SEC on November 8, 2021)

Third Amendment to Amended and Restated Employment Agreement, dated September 20, 2021, by and between the Registrant and Dr. Charles M. Baum (Filed With SEC on November 8, 2021)

Collaboration and License Agreement, dated May 28, 2021, by and among the Company and Zai Lab (Hong Kong) Limited (Filed With SEC on August 5, 2021)

Second Amendment to Letter Agreement, effective December 31, 2020, by and between the Registrant and Dr. James Christensen (Filed With SEC on May 6, 2021)

Second Amendment to Letter (Filed With SEC on May 6, 2021)

Letter Agreement, dated December 18, 2019, by and between the Registrant and Benjamin Hickey (Filed With SEC on February 25, 2021)

Letter Agreement, dated December 20, 2019, by and between the Registrant and Dan Faga (Filed With SEC on February 25, 2021)

Seventh Amendment to Lease to 9393 Towne Centre, dated November 30, 2020 (Filed With SEC on February 25, 2021)

Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on February 25, 2021)

Description of Capital Stock (Filed With SEC on February 25, 2021)

Sixth Amendment to Lease to 9393 Towne Centre Drive, dated July 15, 2020 (Filed With SEC on November 4, 2020)

Fifth Amendment to Lease to 9393 Towne Centre Drive, dated March 4, 2020 (Filed With SEC on November 4, 2020)

Underwriting Agreement, dated October 27, 2020 (Filed With SEC on October 28, 2020)

Separation and Release Agreement, dated June 1, 2020, by and between the Registrant and Isan Chen (Filed With SEC on August 6, 2020)

Sales Agreement, dated July 2, 2020, between Mirati Therapeutics, Inc. and Cowen and Company, LLC (Filed With SEC on July 2, 2020)

Separation and Release Agreement, dated January 3, 2020, by and between the Registrant and Jamie Donadio (Filed With SEC on May 7, 2020)

Separation and Release Agreement, dated January 3, 2020, by and between the Registrant and Chris LeMasters (Filed With SEC on May 7, 2020)

Description of Capital Stock (Filed With SEC on February 26, 2020)

Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on February 26, 2020)

Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement under the Amended and Restated 2013 Equity Incentive Plan (Filed With SEC on February 26, 2020)

Underwriting Agreement, dated January 9, 2020 (Filed With SEC on January 10, 2020)

Mirati Therapeutics, Inc. Inducement Plan (Filed With SEC on December 31, 2019)

Form of Stock Option Grant Notice and Stock Option Agreement under Mirati Therapeutics, Inc. Inducement Plan (Filed With SEC on December 31, 2019)

Forms of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement under Mirati Therapeutics, Inc. Inducement Plan (Filed With SEC on December 31, 2019)

Lease to 3545 Cray Court, dated August 22, 2019 (Filed With SEC on November 4, 2019)

Amended and Restated Fourth Amendment to Lease to 9393 Towne Centre Drive, dated August 22, 2019 (Filed With SEC on November 4, 2019)

Amended and Restated 2013 Equity Incentive Plan, as amended, and Form of Stock Option Agreement and Form of Stock Option Grant Notice thereunder (Filed With SEC on August 5, 2019)

Underwriting Agreement, dated June 24, 2019 (Filed With SEC on June 25, 2019)

Clinical Trial Collaboration and Supply Agreement, dated January 3, 2019, by and between Mirati Therapeutics, Inc. and Bristol-Myers Squibb Company, and related Supply/Quality... (Filed With SEC on April 29, 2019)

Drug Discovery Collaboration Option Agreement, dated October 1, 2014, by and between Mirati Therapeutics, Inc. and Array BioPharma Inc., and related amendments dated August 13,... (Filed With SEC on April 29, 2019)

Amended and Restated 2013 Equity Incentive Plan and Form of Stock Option Grant Notice and Form of Stock Option Agreement thereunder (Filed With SEC on February 28, 2019)

Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on February 28, 2019)

Underwriting Agreement, dated January 16, 2019 (Filed With SEC on January 17, 2019)

Third Amendment to Lease to 9393 Towne Centre Drive, dated August 2, 2018 (Filed With SEC on August 7, 2018)

Form of Pre-Funded Warrant (Filed With SEC on June 7, 2018)

Underwriting Agreement, dated June 6, 2018 (Filed With SEC on June 7, 2018)

Collaboration and License Agreement, dated January 7, 2018, by and among Mirati Therapeutics, Inc., MethylGene Inc. and BeiGene, Ltd (Filed With SEC on May 7, 2018)

Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on May 7, 2018)

Second Amendment to Lease to 9393 Towne Centre Drive, dated April 5, 2018 (Filed With SEC on April 10, 2018)

Underwriting Agreement, dated November 16, 2017 (Filed With SEC on November 16, 2017)

Form of Pre-Funded Warrant (Filed With SEC on November 16, 2017)

MIRATI THERAPEUTICS, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY ADOPTED: SEPTEMBER 9, 2014 EFFECTIVE DATE: SEPTEMBER 9, 2014 AMENDED AND RESTATED:... (Filed With SEC on May 4, 2017)

FIRST AMENDMENT TO LEASE (Filed With SEC on March 27, 2017)

AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on March 9, 2017)

AMENDMENT TO LETTER AGREEMENT (Filed With SEC on March 9, 2017)

MIRATI THERAPEUTICS, INC. FORM OF WARRANT TO PURCHASE COMMON STOCK (Filed With SEC on January 6, 2017)

4,350,176 Shares of Common Stock and Pre-Funded Warrants to Purchase 7,258,263 Shares of Common Stock MIRATI THERAPEUTICS, INC. UNDERWRITING AGREEMENT (Filed With SEC on January 6, 2017)

MIRATI THERAPEUTICS, INC. 2013 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: MAY 8, 2013 APPROVED BY THE STOCKHOLDERS: JUNE 21, 2013 AMENDED AND APPROVED BY THE BOARD:... (Filed With SEC on November 3, 2016)

9393 Towne Centre Drive, Suite 200, San Diego, CA 92121 ###-###-#### E ***@*** W mirati.com (Filed With SEC on August 4, 2016)

Mirati Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy Adopted: September 9, 2014 Effective Date: September 9, 2014 Amended and Restated:... (Filed With SEC on March 9, 2016)

2,250,000 Shares MIRATI THERAPEUTICS, INC. UNDERWRITING AGREEMENT (Filed With SEC on September 16, 2015)

2,250,000 Shares MIRATI THERAPEUTICS, INC. UNDERWRITING AGREEMENT (Filed With SEC on January 29, 2015)

3,250,000 Shares MIRATI THERAPEUTICS, INC. UNDERWRITING AGREEMENT (Filed With SEC on October 24, 2013)

WARRANT CERTIFICATE Warrants to Purchase Common Shares of METHYLGENE INC. (Filed With SEC on October 16, 2013)

[] Shares MIRATI THERAPEUTICS, INC. UNDERWRITING AGREEMENT (Filed With SEC on October 16, 2013)

INDEMNITY AGREEMENT (Filed With SEC on October 3, 2013)

SUBLEASE AGREEMENT 9363 Towne Centre Drive, San Diego, California 92121 (Filed With SEC on August 13, 2013)

Category

Industry

Companies

Contracts

Mirati Therapeutics, Inc. Contracts & Agreements